GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Dame Emma Walmsley es el Chief Executive Officer de GSK plc, se unió a la empresa desde 2011.
¿Qué tal es el rendimiento del precio de la acción GSK plc?
El precio actual de GSK plc es de $27.11, ha disminuido un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de GSK plc?
GSK plc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de GSK plc?
La capitalización bursátil actual de GSK plc es $108.4B
¿Es GSK plc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 26 analistas han realizado calificaciones de análisis para GSK plc, incluyendo 5 fuerte compra, 7 compra, 15 mantener, 4 venta, y 5 fuerte venta